PRPO - Precipio, Inc.
| Previous Close | 0.2718 |
| Open | 0.2730 |
| Bid | 0.3000 x 41400 |
| Ask | 0.3002 x 3600 |
| Day's Range | 0.2724 - 0.3020 |
| 52 Week Range | 0.2500 - 1.7500 |
| Volume | 389,327 |
| Avg. Volume | 645,506 |
| Market Cap | 6.949M |
| Beta (3Y Monthly) | 2.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5660 |
| Earnings Date | Nov 15, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
- GlobeNewswire•12 days ago
Precipio and PerkinElmer Collaborate to Provide Solutions for Liquid Biopsy Testing Workflows
Precipio ICE COLD-PCR™ reagents will be sold with PerkinElmer DNA/RNA extraction and isolation products NEW HAVEN, Conn., Nov. 01, 2018 -- Specialty cancer diagnostics company.
- GlobeNewswire•21 days ago
Precipio Expands ICE COLD-PCR™ Menu for Breast, Colon and Endometrial Cancers
NEW HAVEN, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched two new ICEme™ assays using its proprietary ICE-COLD PCR technology. The new ICEme assays cover PIK3CA exons 9 & 20, and achieve a level of sensitivity of 0.1%, enabling their use with liquid biopsies. PIK3CA mutations occur in about 25% to 40% of breast cancer, 36% of endometrial cancer, and 32% of colon cancers.1 Presence of PIK3CA mutations is associated with resistance to various therapies for breast cancer patients, and in fact have indicated resistance to therapies, thus requiring different or more aggressive treatment.
- GlobeNewswire•26 days ago
Innovation Behind Precipio’s ICE-COLD PCR™ Platform Spotlighted in Media
The scientific and economic advantages of the proprietary, ultra-sensitive ICE-COLD PCR (ICP) technology developed by specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) were recently spotlighted in several industry media outlets. A Drug Delivery Business News article titled “Tracking tumors with Precipio’s liquid biopsy tech” discusses the role liquid biopsies can play in cancer treatment and why the economics of monitoring is important. A Clinical Lab Products article titled “Inside Track: In the Trenches” provides a Q&A with Precipio CEO Ilan Danieli.
- GlobeNewswire•28 days ago
Precipio Announces Third Quarter 2018 Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced preliminary third quarter results representing continued triple digit percentage year-over-year quarterly revenue growth. Pathology services, Precipio’s core business, showed quarter over quarter sequential growth of approximately 20%. Management will review the drivers of pathology services in its upcoming shareholder conference call following the SEC filing of Precipio’s third quarter 2018 results.
- GlobeNewswire•last month
Precipio Launches HemeScreen™, a Disruptive, Proprietary Molecular Test for Hematologic Cancers
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the commercial launch of HemeScreen, a novel proprietary test for mutations in hematologic cancers. Precipio is the first to offer a low cost, rapid molecular screening panel for hematologic mutations. Reagents: A set of RUO reagents sold to other reference labs to perform the test in their CLIA laboratories.
- GlobeNewswire•2 months ago
Precipio Granted 180 Day NASDAQ Extension to Regain Compliance
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced notification by the NASDAQ Stock Market that the Company has been granted a 180-day extension to allow the Company to meet the required minimum $1.00 per share closing bid price of its common stock for 10 consecutive business days for continued inclusion on the Nasdaq Capital Market Exchange. “These additional six months provide more time for our operational, commercial and strategic initiatives to materialize, and for management to build the value of the company,” commented Ilan Danieli, Precipio’s CEO.
- GlobeNewswire•2 months ago
Precipio Enters into Exchange Agreement to Restructure Remaining Legacy Accounts Payable for approximately 20% of Original ~$5M
Specialty cancer diagnostics Company Precipio, Inc. (NASDAQ: PRPO), announces the restructuring of its remaining legacy, pre-merger accounts payable liabilities, pursuant to an exchange which is made in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933. The payments made to note holders are equal to approximately 20% of the original $5.3 million, and are funded through a convertible note with existing investors. Important benefits of this transaction include the postponement of $82,000 in monthly debt service for a period of 12 months, and the ability during that time to convert the notes at a 65% premium to market, effectively reducing by almost half the dilution that would have otherwise resulted from raising capital necessary to satisfy these obligations.
- GlobeNewswire•2 months ago
Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering
The kit provides physicians the ability to use a liquid biopsy to identify patients eligible for Tyrosine Kinase Inhibitor (TKI) therapies through analysis of tumor DNA for these critical EGFR mutations. The presence of such mutations indicates the patient’s eligibility for various targeted therapies including TKI. This kit complements Precipio’s previously-launched TKI-resistance detection kit, providing the clinician with a full suite of sequential lung-cancer diagnostic tools critical to determining patient treatment.
- ACCESSWIRE•3 months ago
Precipio, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Precipio, Inc. (NASDAQ: PRPO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 23, 2018 at 9:00 AM Eastern Time. To ...
- GlobeNewswire•3 months ago
Precipio Reminds Investors of Conference Call with Management for Corporate Update and Second Quarter Results
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), wishes to remind investors and shareholders of its previously announced shareholder conference call scheduled for tomorrow, Thursday August 23, 2018 at 9:00 am EDT, where management will provide a strategic business update and address questions submitted in advance via email. All callers should ask for the Precipio Inc., conference call. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.
- GlobeNewswire•3 months ago
Precipio Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has filed its form 10-Q and released it’s financial results for the second quarter ended June 30, 2018. All callers should ask for the Precipio Inc., conference call. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.
- ACCESSWIRE•4 months ago
Today’s Research Reports on Stocks to Watch: Texas Instruments and Precipio
NEW YORK, NY / ACCESSWIRE / July 19, 2018 / Texas Instruments Incorporated closed down modestly on Wednesday. The company's CEO Brian Crutcher recently resigned for violating conduct and in his place, former CEO Rich Templeton has taken his position. Shares of Precipio saw big gains after announcing preliminary second quarter results.
- ACCESSWIRE•5 months ago
Initiating Free Research Reports on Quest Diagnostics and Three Other Medical Research Equities
Stock Research Monitor: PKI, PRAH, and PRPO LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on DGX sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...
- Simply Wall St.•6 months ago
Who Owns Most Of Precipio Inc (NASDAQ:PRPO)?
In this analysis, my focus will be on developing a perspective on Precipio Inc’s (NASDAQ:PRPO) latest ownership structure, a less discussed, but important factor. A company’s ownership structure is oftenRead More...
- ACCESSWIRE•6 months ago
Complimentary Technical Snapshots on Thermo Fisher Scientific and Three More Medical Research Stocks
Ahead of today's trading session, WallStEquities.com scans four Medical Laboratories and Research stocks, particularly: PerkinElmer Inc. (NYSE: PKI), Precipio Inc. (NASDAQ: PRPO), Syneos Health Inc. (NASDAQ: SYNH), and Thermo Fisher Scientific Inc. (NYSE: TMO). Medical laboratories are independent, commercial enterprises that provide information to the health care professionals about the severity, onset, and reason of patients' physical ailments.
